Elsevier, Biology of Blood and Marrow Transplantation, 4(19), p. 597-601, 2013
DOI: 10.1016/j.bbmt.2012.12.018
Full text: Unavailable
Hyperferritinemia has been associated with adverse outcome after allogeneic hematopoietic cell transplantation (allo-HCT) with myeloablative conditioning. However, its characteristics and impact on the outcome in the reduced-intensity conditioning (RIC) and in the lymphoid malignancies settings are far from clear. The study includes 201 adult patients undergoing allo-HCT with RIC (allo-RIC) for lymphoid malignancies with a median follow-up for survivors of 52 months (range 3-123). Median serum ferritin level at allo-RIC was 379 ng/ml (range 4-10790). In the multivariate analysis, patients with hyperferritinemia at transplant (>399ng/ml) showed lower 4-year overall survival (HR 1.8 [95%CI 1.2-2.8], p=0.008), higher NRM (HR 1.8 [95%CI 1.1-3.2], p=0.03) and higher infection related mortality (HR 2.3 [95%CI 1.1- 4.8], p=0.02) than patients without hyperferritinemia. Neutrophil and platelet engraftment and 100-days NRM were similar between both groups. The adverse outcome associated with hyperferritinemia seemed higher in patients without major comorbidities and it was not influenced by the elevation of acute phase reactants. Our results indicate that high ferritin levels at HCT are associated with an adverse outcome after allo-RIC in patients with lymphoid malignancies.